You are here

Home » SARC Research » SARC Clinical Trials

SARC Clinical Trials

Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world at ClinicalTrials.gov.

Patient participating in sarcoma trial

Active SARC Trials

SU2C - SARC032
A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Type of Sarcoma: Soft Tissue Sarcoma of the Extremity
Drug: Pembrolizumab
Accrual Status: Recruiting
Overall Study Principal Investigator:
David Kirsch, MD, PhD
Professor, Radiation Oncology / Professor of Pharmacology and Cell Biology
Duke University

GO TO CLINICALTRIALS.GOV

SARC033
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Type of Sarcoma: Epithelioid Hemangioendothelioma
Drug: Trametinib
Accrual Status: Not Recruiting
Overall Study Principal Investigator:
Scott Schuetze, MD, PhD
Division of Hematology/Oncology
University of Michigan Comprehensive Cancer Center EDDOP
 

GO TO CLINICALTRIALS.GOV

SARC031
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Drug: Selumetinib in Combination with Sirolimus
Accrual Status: Not Yet Recruiting
Overall Study Principal Investigator:
AeRang Kim, MD, PhD
Pediatric Oncologist
Children’s National Medical Center

Brigitte Widemann, MD
Senior Investigator, Pediatric Oncology Branch
National Cancer Institute
 

GO TO CLINICALTRIALS.GOV

SARC028
A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
Type of Sarcoma: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
Drug: Pembrolizumab
Accrual Status: Not Recruiting
Overall Study Principal Investigator:
Hussein Tawbi, MD, PhD
Associate Professor of Medicine
The University of Texas MD Anderson Cancer Center

GO TO CLINICALTRIALS.GOV

SARC024
A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Type of Sarcoma: Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas and Rhabdomyosarcoma
Drug: Regorafenib
Accrual Status: Recruiting
Overall Study Principal Investigator:
Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory

 

GO TO CLINICALTRIALS.GOV

ESP1 / SARC025
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma
Type of Sarcoma: Ewing Sarcoma
Drug: Niraparib, Temozolomide and Irinotecan
Accrual Status: Not Recruiting
Overall Study Principal Investigator:
Sandra Strauss, MBBS, PhD
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute

Rashmi Chugh, MD
Assistant Professor
University of Michigan

GO TO CLINICALTRIALS.GOV

Closed SARC Trials

SARC023
A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: Phase I all unresectable soft tissue or bone sarcomas and Phase II unresectable malignant peripheral nerve sheath tumor (MPNST)
Drug: Ganetespib and Sirolimus
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC022
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
Type of Sarcoma: Gastrointestinal stromal tumors
Drug: OSI-906
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC021
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Type of Sarcoma: Locally advanced or metastatic soft tissue sarcoma
Drug: TH-302 combined with doxorubicin vs. doxorubicin alone
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC020
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Type of Sarcoma: Advanced or Metastatic Untreated Soft Tissue Sarcoma
Drug: Trabectedin Infused to Doxorubicin
Accrual Status: Terminated

GO TO CLINICALTRIALS.GOV

SARC019
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Type of Sarcoma: Metastatic GIST
Drug: Imatinib
Accrual Status: Terminated

GO TO CLINICALTRIALS.GOV

SARC018 - SPORE01
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Type of Sarcoma: Metastatic Leiomyosarcoma
Drug: Mocetinostat & Gemcitabine
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC016
Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: Malignant Peripheral Nerve Sheath Tumor (MPNST) either Sporadic or NF1 Associated
Drug: Bevacizumab and Everolimus
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC012
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Type of Sarcoma: Osteosarcoma
Drug: Saracatinib and Placebo
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC011
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
Type of Sarcoma: Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma
Drug: R1507
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC009
Trial of Dasatinib in Advanced Sarcomas
Type of Sarcoma: Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST)
Drug: Dasatinib
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC007
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
Type of Sarcoma: Chondrosarcoma, extra-skeletal myxoid chondrosarcoma or alveolar soft part sarcoma
Drug: Perifosine
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC006
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Type of Sarcoma: Malignant peripheral nerve sheath tumors sporadic or NF1 associated
Drug: Adriamycin/ifosfamide and Adriamycin/etoposide
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC005
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Type of Sarcoma: Uterine Leiomyosarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC004
Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Type of Sarcoma: Dermatofirbrosarcoma Protuberans
Drug: Gleevec (Imatinib Mesylate)
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV

SARC003
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Type of Sarcoma: Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
Drug: Gemcitabine and Docetaxel
Accrual Status: Completed

GO TO CLINICALTRIALS.GOV